Abstract

Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC)
Michael Davis ... Mothaffar F Rimawi
Cancer Research | VOL. 82
Michael Davis, et. al.Michael Davis ... Mothaffar F Rimawi
15 Feb 2022
Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
Matthew P Goetz ... Nadia Harbeck
Cancer Research | VOL. 83
Matthew P Goetz, et. al.Matthew P Goetz ... Nadia Harbeck
01 Mar 2023
Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER)
Dymphna Lee ... Claire Swift
Cancer Research | VOL. 83
Dymphna Lee, et. al.Dymphna Lee ... Claire Swift
01 Mar 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Hans Joachim Lueck ... Tammy Forrester
Therapeutic advances in medical oncology | VOL. 15
Hans Joachim Lueck, et. al.Hans Joachim Lueck ... Tammy Forrester
01 Jan 2023
View more papers

More From: Cancer Research

Paper Title
Journal
Date
Author
Physical Activity Decreases Inflammation and Delays Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma.
Valentina Pita-Grisanti ... Zobeida Cruz-Monserrate
Cancer research | VOL. -
Valentina Pita-Grisanti, et. al.Valentina Pita-Grisanti ... Zobeida Cruz-Monserrate
22 May 2024
FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis.
Dan Su ... Taiping Zhang
Cancer research | VOL. -
Dan Su, et. al.Dan Su ... Taiping Zhang
22 May 2024
Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance.
Yi Sui ... Yujie Tang
Cancer research | VOL. -
Yi Sui, et. al.Yi Sui ... Yujie Tang
22 May 2024
Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer.
Hua Ma ... Peter Caravan
Cancer research | VOL. -
Hua Ma, et. al.Hua Ma ... Peter Caravan
17 May 2024
View more papers